• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Intra-Cellular Ther (NQ: ITCI )

    86.54 +1.79 (+2.11%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Intra-Cellular Ther

    < Previous 1 2 3 4 5 Next >
    Looking Into Intra-Cellular Therapies's Return On Capital Employed
    Benzinga Pro data, Intra-Cellular Therapies (NASDAQ:ITCI) reported Q3 sales of $22.21 million. Earnings fell to a loss of $77.32 million, resulting in a 11.83% decrease from last... 
    Via Benzinga
    Intra-Cellular Therapies inc (ITCI) Q3 2021 Earnings Call Transcript
    ITCI earnings call for the period ending September 30, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Intra-Cellular Therapies: Q3 Earnings Insights
    Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the... 
    Via Benzinga
    Two Trillion-Dollar Industries Being Transformed By Tech
    FN Media Group Presents Oilprice.com Market Commentary London – October 20, 2021 – Big money is pouring into two disruptive segments in two of the world’s biggest industries – healthcare and energy.... 
    Via FinancialNewsMedia
    Looking Into Intra-Cellular Therapies's Return On Capital Employed
    Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $20.05 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 29.92%, resulting... 
    Via Benzinga
    The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
    Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
    Via Benzinga
    Exposures Product Safety
    Earnings Scheduled For May 10, 2021
    Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
    Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ: 
    Via Benzinga
    Why Intra-Cellular Therapies Was Weak This Week
    The company's second-quarter net loss was a bit deeper than analysts expected. 
    Via The Motley Fool
    Intra-Cellular Therapies inc (ITCI) Q2 2021 Earnings Call Transcript
    ITCI earnings call for the period ending June 30, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Intra-Cellular Therapies: Q2 Earnings Insights
    Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share rose 11.46% over the past year... 
    Via Benzinga
    Pandemic Fallout: 6 Mental Health Stocks To Watch
    One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people’s mental health. The next globa... 
    Via Benzinga
    Exposures COVID-19
    Looking Into Intra-Cellular Therapies's Return On Capital Employed
    During Q1, Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $15.88 million. However, earnings decreased 13.23%, resulting in a loss of $53.22 million. In Q4, Intra... 
    Via Benzinga
    The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,... 
    Via Benzinga
    Exposures COVID-19 Product Safety
    Earnings Scheduled For August 9, 2021
    Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
    Via Benzinga
    The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ... 
    Via Benzinga
    Biotechs Ready To Roar
    The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
    Via Talk Markets
    Exposures Product Safety
    The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) AngioDynamics, Inc. (NASDAQ... 
    Via Benzinga
    The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
    Via Benzinga
    Stocks That Hit 52-Week Highs On Tuesday
    Before 10 a.m. ET Tuesday, 59 stocks made new 52-week highs. Intriguing Points: Microsoft (NASDAQ:MSFT) was the company with the largest market cap to set a new 52-week... 
    Via Benzinga
    The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Aethlon Medical, Inc. (... 
    Via Benzinga
    The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
    Via Benzinga
    The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc... 
    Via Benzinga
    Looking Into Intra-Cellular Therapies's Return On Capital Employed
    During Q1, Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $15.88 million. However, earnings decreased 13.23%, resulting in a loss of $53.22 million. In Q4, Intra... 
    Via Benzinga
    The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... 
    Via Benzinga
    Intra-Cellular Therapies Inc (ITCI) Q1 2021 Earnings Call Transcript
    ITCI earnings call for the period ending March 31, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Recap: Intra-Cellular Therapies Q1 Earnings
    Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share rose 10.96% over the past year... 
    Via Benzinga
    The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
    Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
    Via Benzinga
    Exposures COVID-19 Product Safety
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.